Want to join the conversation?
Jon Groberg of UBS asks about the outlook for 2017. $A said it has a rich pipeline of new product introductions coming in 4Q16 and in FY17. $A expects pharma and China markets to be significant growth drivers but believes they will be below double digit levels. $A is forecasting low single digit growth for FY17.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)